Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv, Ukraine.
J Med Chem. 2011 Apr 28;54(8):2680-6. doi: 10.1021/jm200117h. Epub 2011 Mar 30.
Apoptosis signal-regulating kinase 1 (ASK1) has recently emerged as an attractive therapeutic target for the treatment of cardiac and neurodegenerative disorders. The selective inhibitors of ASK1 may become important compounds for the development of clinical agents. We have identified the ASK1 inhibitor among 3H-naphtho[1,2,3-de]quinoline-2,7-diones using receptor-based virtual screening. In vitro kinase assay revealed that ethyl 2,7-dioxo-2,7-dihydro-3H-naphtho[1,2,3-de]quinoline-1-carboxylate (NQDI-1) inhibited ASK1 with a K(i) of 500 nM. The competitive character of inhibition is demonstrated in Lineweaver-Burk plots. In our preliminary selectivity study this compound exhibited strong specific inhibitory activity toward ASK1.
凋亡信号调节激酶 1(ASK1)最近成为治疗心脏和神经退行性疾病的有吸引力的治疗靶点。ASK1 的选择性抑制剂可能成为开发临床药物的重要化合物。我们使用基于受体的虚拟筛选从 3H-萘并[1,2,3-de]喹啉-2,7-二酮中鉴定出 ASK1 抑制剂。体外激酶测定显示,乙基 2,7-二氧代-2,7-二氢-3H-萘并[1,2,3-de]喹啉-1-羧酸酯(NQDI-1)以 500 nM 的 K(i)抑制 ASK1。在 Lineweaver-Burk 图中证明了抑制的竞争性特征。在我们的初步选择性研究中,该化合物对 ASK1 表现出强烈的特异性抑制活性。